Back to the list
Congress: ECR25
Poster Number: C-12112
Type: Poster: EPOS Radiologist (educational)
DOI: 10.26044/ecr2025/C-12112
Authorblock: P. Escobosa García, S. A. Bolivar, D. Castellón Plaza, B. Del Río Carrero, H. I. Jofre Grimaldo, A. M. Díaz Cárdenas, A. Medina Gómez, P. C. Notta, D. A. Sandoval Díaz; L'Hospitalet de Llobregat (Barcelona)/ES
Disclosures:
Paula Escobosa García: Nothing to disclose
Santiago A Bolivar: Nothing to disclose
Daniel Castellón Plaza: Nothing to disclose
Belén Del Río Carrero: Nothing to disclose
Héctor Ignacio Jofre Grimaldo: Nothing to disclose
Angela María Díaz Cárdenas: Nothing to disclose
Antonio Medina Gómez: Nothing to disclose
Paula Cecilia Notta: Nothing to disclose
Daniel Alejandro Sandoval Díaz: Nothing to disclose
Keywords: Cardiac, Hybrid Imaging, Nuclear medicine, MR, PET-MR, Diagnostic procedure, Education, Imaging sequences, Inflammation, Tissue characterisation
Learning objectives To describe the clinical manifestations and diagnostic criteria of cardiac sarcoidosis (CS).To analyze MRI characteristics of CS, focusing on late gadolinium enhancement (LGE), and evaluate the impact of early detection on diagnostic accuracy and patient outcomes.To highlight recent advancements in hybrid PET/MRI and how an integrated approach enhances the diagnosis and evaluation of CS.
Read more Background Sarcoidosis is a multisystem inflammatory disease of unknown origin, characterized by non-caseating granulomas that affect various organs, including the heart. Diagnosing CS presents significant challenges. While endomyocardial biopsy is considered the gold standard, it often has limited sensitivity due to the patchy distribution of the disease. Moreover, clinical presentations are nonspecific, ranging from asymptomatic to severe manifestations. As a result, the diagnostic criteria established by the Japanese Circulation Society (JCS) emphasize a multimodal diagnostic approach, highlighting the essential role of...
Read more Findings and procedure details 1. IntroductionCS is a rare but potentially fatal manifestation of systemic sarcoidosis and remains a leading cause of death in affected patients. Although clinical cardiac involvement occurs in 3-5% of cases, autopsy findings show CS in up to 20-30%, highlighting the challenge of diagnosing it during life. Consequently, recent advancements in imaging techniques, particularly cardiac MRI and 18F-FDG PET/CT, have improved diagnostic accuracy, overcoming the limited sensitivity of myocardial biopsy. Furthermore, hybrid PET/MRI offers a synergistic method to assess both...
Read more Conclusion Cardiac involvement remains a significant and potentially fatal manifestation of sarcoidosis. The diagnosis and management of CS remain challenging due to its diverse presentations and the limitations of biopsy. Current international guidelines emphasize a multimodal diagnostic approach, where advanced imaging techniques, such as cardiac MRI with LGE and PET, play a crucial role in diagnosis, disease monitoring, and risk stratification.The integration of PET with MRI represents a significant advancement, maintaining MRI's diagnostic sensitivity while incorporating PET's ability to detect inflammation....
Read more References Kouranos V, Sharma R. Cardiac sarcoidosis: state-of-the-art review. Heart. 2021;107(19):1591-9. Vignaux O. Cardiac sarcoidosis: spectrum of MRI features. Am J Roentgenol. 2005;184(1):249-54. Manabe O, Yoshinaga K, Ohira H, Schatka I, Kudo T, Tamaki N. Advances in diagnostic imaging for cardiac sarcoidosis. J Clin Med. 2021;10(24):5808. Stanton KM, Jenkins C, Anderson L, McGhie J, Holloway CJ. The utility of cardiac magnetic resonance imaging in the diagnosis of cardiac sarcoidosis. Heart Lung Circ. 2017;26(11):1191-9. Terasaki F, Ishizaka N, Noda M, Ikeda Y, Sekiguchi K, Shimokawa H,...
Read more
GALLERY